Screener
Baxter International BAX Pharmaceuticals — Research and development expenses
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Baxter International in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Baxter International’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-028962
| (in millions) | Three Months Ended March 31, 2026 / Medical Products & Therapies | Three Months Ended March 31, 2026 / Healthcare Systems & Technologies | Three Months Ended March 31, 2026 / Pharmaceuticals | Three Months Ended March 31, 2025 / Medical Products & Therapies | Three Months Ended March 31, 2025 / Healthcare Systems & Technologies | Three Months Ended March 31, 2025 / Pharmaceuticals |
|---|---|---|---|---|---|---|
| Net sales | $1,285 | $705 | $621 | $1,262 | $704 | $581 |
| Cost of sales | 781 | 390 | 458 | 694 | 356 | 396 |
| Selling, general and administrative expenses | 290 | 209 | 102 | 286 | 217 | 103 |
| Research and development expenses | 54 | 49 | 22 | 59 | 45 | 26 |
| Other segment items | (26) | (9) | (7) | (21) | (7) | (7) |
| Segment operating income | $186 | $66 | $46 | $244 | $93 | $63 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Baxter International's pharmaceuticals — research and development expenses?
- Baxter International (BAX) reported pharmaceuticals — research and development expenses of $22M in Q1 2026.
- How has Baxter International's pharmaceuticals — research and development expenses changed year-over-year?
- Baxter International's pharmaceuticals — research and development expenses decreased by 15.4% year-over-year, from $26M to $22M.
- What is the long-term trend for Baxter International's pharmaceuticals — research and development expenses?
- Over 3 years (2022 to 2025), Baxter International's pharmaceuticals — research and development expenses has grown at a 7.6% compound annual growth rate (CAGR), from $81M to $101M.
- What does pharmaceuticals — research and development expenses mean?
- Reflects the investment in innovation, clinical trials, and product development specifically for the Pharmaceuticals segment. This spending is critical for maintaining a competitive pipeline and long-term product viability.
Ask your AI about Baxter International's pharmaceuticals — research and development expenses.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude